MassBio is excited to announce our first-ever Partnering Week! This week-long event connects early-stage companies developing breakthrough technologies with major biopharmaceutical organizations.
Register today to attend our public sponsor overview sessions, where one sponsor each day will present on their research and development strategy, partnering approaches, therapeutic areas, and 2021 outlook. After each session, participants can engage with our sponsors for Q&A via our event platform. Registration grants you access to all four sponsor overview sessions.
MassBio encourages early-stage companies, academic institutions, principal investigators, and venture funds to request a one-on-one meeting with sponsor organizations. Learn more about the sponsor organizations and request a meeting here.
All overview sessions will take place from 10:00 AM – 11:00 AM.
Monday, January 25 from 10:00 AM – 11:00 AM
Johnson & Johnson Innovation
Tuesday, January 26 from 10:00 AM – 11:00 AM
Wednesday, January 27 from 10:00 AM – 11:00 AM
Thursday, January 28 from 10:00 AM – 11:00 AM
|Session Title||Start Time||End Time|
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain. Partnerships and collaborations are critical to building our neuroscience innovation ecosystem.
|1/25/2021 10:00 AM||1/25/2021 11:00 AM|
Johnson & Johnson Innovation Plenary
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists and entrepreneurs with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. We connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients.
|1/26/2021 10:00 AM||1/26/2021 11:00 AM|
EMD Serono Plenary
EMD Serono aspires to create, improve and prolong life for people living with difficult-to-treat conditions like multiple sclerosis, cancer and infertility. We’re imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. Our company’s global roots take us back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, we have approximately 1,500 employees around the country with commercial, clinical and research operations based in our home state of Massachusetts.
|1/27/2021 10:00 AM||1/27/2021 11:00 AM|
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,200+ employees in China, the U.S., Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the U.S. and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
|1/28/2021 10:00 AM||1/28/2021 11:00 AM|